• Cytophage receives Letters of No Objection (LONO) from Health Canada for two of its cutting-edge bacteriophage products 

• Regulatory milestone accelerates Cytophage’s path to commercialization and broader market access 

• Canada aligns with the EU and US in accepting phage technology, advancing antibiotic-free food solutions 

WINNIPEG – TheNewswire - August 25, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that it is in receipt of two Letters of No Objection (“LONO”) from Health Canada regarding its OvaPhage egg surface product and its PhageFend food surface product, marking a major regulatory milestone that will help pave the way for the introduction of innovative, science-driven solutions to enhance food safety in the Canadian market.

The LONO validations affirm the safety and efficacy of bacteriophage technology for use in food processing, with OvaPhage now in the final stages of development and advancing towards commercialization.

Phage treatments present an alternative to antibiotics which are known contributors to global antimicrobial resistance (“AMR”). With these validations, Canada is recognizing and accepting phage technology for food safety and antibiotic-free food options. The LONO notifications are also a crucial step forward in granting phage products market access under a regulated path in Canada.

“This milestone underscores our unwavering commitment to eliminating bacterial diseases and infections,” said Dr. Steven Theriault, CEO of Cytophage. “We are proud to lead the way in demonstrating that phage-based solutions can be safe and effective tools for enhancing food safety and security, especially in light of the current Salmonella outbreaks related to pistachio and salami contamination in Canada. By expanding access to our innovative phage products, we aim to significantly reduce reliance on antibiotics in food systems—offering a sustainable approach to combating the global threat of antimicrobial resistance.”

Details on Notifications:

• The letters serve as a formal notification by Health Canada’s Food Directorate that the OvaPhage and PhageFend bacteriophage products can be used in food processing and food production.  

• Cytophage’s application included comprehensive data and scientific evidence demonstrating the safety and efficacy of both products, which were thoroughly evaluated by Health Canada and led to the issuance of the LONO notifications. 

• The first LONO notification states that Health Canada evaluated the data provided and concluded that OvaPhage is effective at reducing Salmonella, Escherichia, and Shigella bacteria (Enterobacteriaceae) on the surface of eggs. 

• The second LONO notification states that Health Canada evaluated the data and concluded that the PhageFend is effective at reducing Salmonella enterica on raw skinless and boneless chicken breasts. 

Cytophage is now positioned to finalize the product development of OvaPhage for egg producers and PhageFend for meat processing facilities, enabling a more effective removal of bacteria from surfaces. The Company continues to work with its OvaPhage commercial research partner to determine the most effective dosage and application processes for commercial settings.

This regulatory success should pave the way for future approvals of phage products, including those for animal feed and potentially ultimately for therapeutic use in humans, thereby advancing the global fight against antibiotic resistance.

About Cytophage 
Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. 

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature’s version of antibiotics. 

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products. 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

For further information please contact:  

Heather Medwick, Chief Operating Officer 
heather@cytophage.com | 431 388 8873 

Cytophage Investor Alerts: https://cytophage.com/subscribe/

Cautionary Statement on Forward-Looking Information 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.